Cool Down: US FDA’s July User Fee Calendar Suggests Slower Pace After Torrid June

FDA action is expected on a handful of novel agents, including Daiichi Sankyo’s quizartinib, and conversion to full approval for Eisai/Biogen’s Leqembi.